1-{5-[(4-fluoro-2-methylbenzyl)oxy]-1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-pyrazolo-3-yl}-N-methylmethanamine | 1355349-76-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-{5-[(4-fluoro-2-methylbenzyl)oxy]-1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-pyrazolo-3-yl}-N-methylmethanamine
• 英文别名: US10183913, Example 108；1-[5-[(4-fluoro-2-methylphenyl)methoxy]-1-(oxan-2-ylmethyl)pyrazol-3-yl]-N-methylmethanamine
• CAS: 1355349-76-6
• 化学式: C₁₉H₂₆FN₃O₂
• 分子量: 347.433
• InChiKey: XBQUDSPZDCKBOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  48.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：EP3569233A1

  公开（公告）日：2019-11-20

  The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.

  本发明的目的是提供：一种治疗5-羟色胺能系统或多巴胺能系统相关疾病，特别是帕金森病的精神功能障碍症状和其他非运动症状的治疗剂或复发预防剂；以及一种治疗上述症状或预防上述症状复发的方法。由式(1)代表的化合物[其中各符号如描述中所定义]或其药学上可接受的盐可以显示出治疗血清素能系统或多巴胺能系统相关疾病的效果，特别是精神功能障碍症状和帕金森病的其他非运动症状，和/或防止其复发的效果。